UGT1A1 and cancer: Although a recent meta-analysis performed to analyze the difference in adverse reaction and therapeutic response (TR) between IRI-administered cancer patients with different UGT1A1*6 genotypes [21], and explored the association between cancer and UGT1A1*6, and performed the subgroup analysis; the association between CRC and UGT1A1*6 did not explain deeply.